TRIM5/21/22/24/28/34/47 exhibited positive correlations, while TRIM17 exhibited negative correlations, which indicated that patients with gliomas with high expression of TRIM5/21/22/24/28/34/47 or low expression of TRIM17 may benefit from emerging immunotherapy, despite the implications for poorer prognosis. This evidence concerns the gene TRIM5 and central nervous system cancer.